Ophthalmology Innovation Summit

Ophthalmology Innovation Summit

October 10, 2019
1 min watch
Save

VIDEO: Phase 2b results positive for Orasis presbyopia-correcting drops

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — Elad Kedar, CEO of Orasis Pharmaceuticals, discusses results of a phase 2b trial of the company’s CSF-1 eye drop formulation for presbyopia correction at the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology annual meeting. Positive safety, durability and efficacy results were demonstrated, he said.